Pharming Group N.V. (NASDAQ: PHAR) shares surged 20.11% in pre-market trading on Thursday, following the release of its impressive third-quarter 2025 financial results. The Dutch biopharmaceutical company reported significant growth in revenue and profitability, beating analyst expectations and raising its full-year guidance.

The company's total revenues for Q3 2025 increased by 30% year-over-year to $97.3 million, surpassing the analyst consensus estimate of $93.43 million. Pharming reported quarterly earnings of $0.10 per share, significantly beating the analyst estimate of breakeven results. This represents a substantial improvement from the $0.02 loss per share in the same period last year.

Key highlights from the report include a 29% increase in RUCONEST® revenues to $82.2 million and a 35% growth in Joenja® (leniolisib) revenues to $15.1 million. The company's operating profit surged by an impressive 285% to $15.8 million. Based on this strong performance, Pharming raised its full-year 2025 revenue guidance to $365-$375 million from the previous $335-$350 million range. The positive results were attributed to sustained growth in patients and prescribers for both RUCONEST® and Joenja®, as well as advancements in the company's product pipeline, including the FDA granting priority review for leniolisib in pediatric patients with APDS.